VivoSeq
Neurology

Myotonic Dystrophy Type 1 (DM1)

2

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Myotonic Dystrophy Type 1 (DM1) is an early-stage landscape with 2 programs across 3 companies. The most active players are Vertex Pharmaceuticals, Dyne Therapeutics, Eli Lilly. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

1 program

Phase 2D

Dyne Therapeutics

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

VX-670

Vertex Pharmaceuticals

Phase 31

DYNE-101

Dyne Therapeutics

Approved
No programs

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Enrolling by invitation1 · 50%

Clinical Trials

Trial Activity

A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants With Myotonic Dystrophy Type 1
Recruiting·DDyne Therapeutics·Phase 3·NCT07486934·150 enrolled
An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type I
Enrolling by invitation·Vertex Pharmaceuticals logoVertex Pharmaceuticals·Phase 2·NCT06926621·44 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)